[go: up one dir, main page]

WO2014044793A3 - Cd22-binding peptides - Google Patents

Cd22-binding peptides Download PDF

Info

Publication number
WO2014044793A3
WO2014044793A3 PCT/EP2013/069569 EP2013069569W WO2014044793A3 WO 2014044793 A3 WO2014044793 A3 WO 2014044793A3 EP 2013069569 W EP2013069569 W EP 2013069569W WO 2014044793 A3 WO2014044793 A3 WO 2014044793A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding peptides
antibody
derived
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/069569
Other languages
French (fr)
Other versions
WO2014044793A2 (en
Inventor
Oliver Schmetzer
Antonio Pezzutto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of WO2014044793A2 publication Critical patent/WO2014044793A2/en
Publication of WO2014044793A3 publication Critical patent/WO2014044793A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to synthetic non-antibody-derived CD22-binding peptides for antibody mimetics, as active agents or as targeting agents for immune conjugates.
PCT/EP2013/069569 2012-09-20 2013-09-20 Cd22-binding peptides Ceased WO2014044793A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185135.6 2012-09-20
EP12185135 2012-09-20

Publications (2)

Publication Number Publication Date
WO2014044793A2 WO2014044793A2 (en) 2014-03-27
WO2014044793A3 true WO2014044793A3 (en) 2014-05-08

Family

ID=46888950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/069569 Ceased WO2014044793A2 (en) 2012-09-20 2013-09-20 Cd22-binding peptides

Country Status (1)

Country Link
WO (1) WO2014044793A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
JP7369121B2 (en) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド How to induce complement activity
JP7637052B2 (en) * 2018-12-19 2025-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Bispecific anti-CD28X anti-CD22 antibodies and uses thereof
CN109432087A (en) * 2018-12-21 2019-03-08 陕西师范大学 Ellagic acid prevents and treats the application in multiple sclerosis agent in preparation
CA3173325A1 (en) 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106368A1 (en) * 2003-05-28 2004-12-09 Scil Proteins Gmbh Generation of artificial binding proteins based on ubiquitin proteins
US20070015181A1 (en) * 2000-05-19 2007-01-18 Williams Richard B System and methods for nucleic acid and polypeptide selection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015181A1 (en) * 2000-05-19 2007-01-18 Williams Richard B System and methods for nucleic acid and polypeptide selection
WO2004106368A1 (en) * 2003-05-28 2004-12-09 Scil Proteins Gmbh Generation of artificial binding proteins based on ubiquitin proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVID PEARSON ET AL: "CD22-Binding Peptides Derived from Anti-CD22 Ligand Blocking Antibodies Retain the Targeting and Cell Killing Properties of the Parent Antibodies and May Serve as a Drug Delivery Vehicle", INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS ; FORMERLY KNOWN AS LETTERS IN PEPTIDE SCIENCE, KLUWER ACADEMIC PUBLISHERS, DO, vol. 14, no. 3, 1 August 2008 (2008-08-01), pages 237 - 246, XP019610949, ISSN: 1573-3904 *
ROTHE A ET AL: "IN VITRO DISPLAY TECHNOLOGIES REVEAL NOVEL BIOPHARMACEUTICS", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, US, vol. 20, no. 10, 1 August 2006 (2006-08-01), pages 1599 - 1610, XP009082600, ISSN: 0892-6638, DOI: 10.1096/FJ.05-5650REV *
ROTHE ACHIM ET AL: "Ribosome display and selection of human anti-CD22 scFvs derived from an acute lymphocytic leukemia patient", BIOLOGICAL CHEMISTRY, WALTER DE GRUYTER GMBH & CO, BERLIN, DE, vol. 389, no. 4, 1 April 2008 (2008-04-01), pages 433 - 439, XP009119557, ISSN: 1431-6730, DOI: 10.1515/BC.2008.045 *

Also Published As

Publication number Publication date
WO2014044793A2 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
MX2019003214A (en) Stable dual variable domain immunoglobulin protein formulations.
WO2014191113A8 (en) Novel antibodies
EA201992456A3 (en) SELF-STABILIZING LINKER CONJUGATES
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
IL236348A0 (en) Anti-jagged antibodies, compositions comprising the same and uses thereof
WO2011123820A3 (en) Single isomeric conjugates of rhodamine dyes
HK1218549A1 (en) Novel antibody frameworks
EP3088518A4 (en) Novel anti-transferrin receptor antibody that passes through blood-brain barrier
HK1207665A1 (en) Polypeptides having transgalactosylating activity
EP3736282C0 (en) CELL-PENETRATING PEPTIDE, CONJUGATE COMPRISING THEM, AND COMPOSITION COMPRISING THE CONJUGATE
EA201401254A1 (en) САМОСТАБИЛИЗИРУСЩИЕСЯ ЛИНКЕРНЫЕ КОНЪЮГАТЫ
HK1207654A1 (en) Modified antibody regions and uses thereof
EA201590173A1 (en) IMMUNOCONGUTS CONTAINING ANTIBODIES TO CD22
BR112013020383A2 (en) lyophilized formulations.
WO2014078268A3 (en) Anti-hemagglutinin antibodies and methods of use
HK1204973A1 (en) Diclofenac formulations
WO2013026004A3 (en) Antibodies that bind integrin alpha-v beta-8
TR201905787T4 (en) Lyophilized TAT-NR2B9C formulation.
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
EP2885321A4 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
WO2012064743A3 (en) Methods for improving heart function
WO2014044793A3 (en) Cd22-binding peptides
WO2014033158A3 (en) Pcsk9 peptide vaccine
MX2015006616A (en) Dual targeting.
HK1215571A1 (en) Cobicostat dichlohydrate salt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13765732

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13765732

Country of ref document: EP

Kind code of ref document: A2